Inventor · disambiguated record
Hiroyuki Tsunoda
Also filed as: TSUNODA HIROYUKI
31 granted patents·39 pending applications·749 citations·filing 2001–2025
98Inventor score
Top patents by PatentIndex Score
70 records- 0198US12122840B2Method of modifying isoelectric point of antibody via amino acid substitution in CDRCHUGAI PHARMACEUTICAL CO LTD·Filed 2024·Granted Oct 22, 2024·5 cites·24 claims
- 0298US12116414B2Method of modifying isoelectric point of antibody via amino acid substitution in CDRCHUGAI PHARMACEUTICAL CO LTD·Filed 2024·Granted Oct 15, 2024·5 cites·21 claims
- 0398US11168344B2Methods for producing polypeptides by regulating polypeptide associationCHUGAI PHARMACEUTICAL CO LTD·Filed 2017·Granted Nov 9, 2021·18 cites·39 claims
- 0498US10934344B2Methods of modifying antibodies for purification of bispecific antibodiesCHUGAI PHARMACEUTICAL CO LTD·Filed 2017·Granted Mar 2, 2021·19 cites·30 claims
- 0598US10011858B2Methods for producing polypeptides by regulating polypeptide associationIGAWA TOMOYUKI·Filed 2006·Granted Jul 3, 2018·67 cites·54 claims
- 0698US9828429B2Method of modifying isoelectric point of antibody via amino acid substitution in CDRCHUGAI PHARMACEUTICAL CO LTD·Filed 2015·Granted Nov 28, 2017·40 cites·80 claims
- 0798US9096651B2Method of modifying isoelectric point of antibody via amino acid substitution in CDRIGAWA TOMOYUKI·Filed 2008·Granted Aug 4, 2015·90 cites·44 claims
- 0898US8562991B2Antibody molecules that bind to IL-6 receptorIGAWA TOMOYUKI·Filed 2009·Granted Oct 22, 2013·130 cites·19 claims
- 0997US11248053B2Method of modifying isoelectric point of antibody via amino acid substitution in CDRCHUGAI PHARMACEUTICAL CO LTD·Filed 2017·Granted Feb 15, 2022·16 cites·28 claims
- 1097US9670269B2Methods of modifying antibodies for purification of bispecific antibodiesIGAWA TOMOYUKI·Filed 2007·Granted Jun 6, 2017·43 cites·25 claims
- 1196US10662245B2Methods of reducing IL-6 activity for disease treatmentCHUGAI PHARMACEUTICAL CO LTD·Filed 2014·Granted May 26, 2020·22 cites·25 claims
- 1296US7919086B2Anti-glypican 3 antibodyCHUGAI PHARMACEUTICAL CO LTD·Filed 2005·Granted Apr 5, 2011·74 cites·56 claims
- 1394US11046784B2Methods for controlling blood pharmacokinetics of antibodiesIGAWA TOMOYUKI·Filed 2007·Granted Jun 29, 2021·24 cites·50 claims
- 1494US8497355B2Anti-glypican-3 antibody having improved kinetics in plasmaIGAWA TOMOYUKI·Filed 2008·Granted Jul 30, 2013·29 cites·16 claims
- 1593US8575317B2Anti-NR10 antibody and use thereofKURAMOCHI TAICHI·Filed 2009·Granted Nov 5, 2013·37 cites·14 claims
- 1693US2025101118A1Antibody moleculesCHUGAI PHARMACEUTICAL CO LTD·Filed 2024·Application pending·0 cites
- 1792US8586039B2Degraded TPO agonist antibodyTSUCHIYA MASAYUKI·Filed 2011·Granted Nov 19, 2013·20 cites·27 claims
- 1892US8008073B2Anti-Mpl antibodiesCHUGAI PHARMACEUTICAL CO LTD·Filed 2010·Granted Aug 30, 2011·12 cites·33 claims
- 1992US2025346677A1Antibody moleculesCHUGAI PHARMACEUTICAL CO LTD·Filed 2025·Application pending·0 cites
- 2091US9399680B2Nucleic acids encoding anti-NR10 antibodiesCHUGAI PHARMACEUTICAL CO LTD·Filed 2013·Granted Jul 26, 2016·17 cites·37 claims
- 2191US2024301075A1Antibody moleculesCHUGAI PHARMACEUTICAL CO LTD·Filed 2024·Application pending·0 cites
- 2291US2025011443A1Method of modifying isoelectric point of antibody via amino acid substitution in cdrCHUGAI PHARMACEUTICAL CO LTD·Filed 2024·Application pending·0 cites
- 2389US9340615B2Anti-AXL antibodyMAEDA ATSUHIKO·Filed 2010·Granted May 17, 2016·23 cites·23 claims
- 2488US2024010738A1Antibody moleculesCHUGAI PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 2588US2024294653A1Anti-nr10 antibody and use thereofCHUGAI PHARMACEUTICAL CO LTD·Filed 2024·Application pending·0 cites
- 2687US8257703B2Anti-ganglioside antibodies and compositionsIRIE REIKO·Filed 2010·Granted Sep 4, 2012·11 cites·20 claims
- 2786US7993642B2Anti-MPL antibodiesCHUGAI PHARMACEUTICAL CO LTD·Filed 2004·Granted Aug 9, 2011·11 cites·27 claims
- 2886US2023159648A1Antibody moleculesCHUGAI PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 2985US10688178B2AntiPlexin A1 agonist antibodyUNIV OSAKA·Filed 2016·Granted Jun 23, 2020·4 cites·22 claims
- 3083US8034903B2Degraded TPO agonist antibodyCHUGAI PHARMACEUTICAL CO LTD·Filed 2001·Granted Oct 11, 2011·8 cites·11 claims
- 3183US2022306755A1Antibody moleculesCHUGAI PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 3282US2023183363A1Anti-nr10 antibody and use thereofCHUGAI PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 3381US9493569B2Structural isomers of sc(Fv)2IGAWA TOMOYUKI·Filed 2006·Granted Nov 15, 2016·7 cites·14 claims
- 3480US2022041741A1Antibody moleculesCHUGAI PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 3580US2022389105A1Method of modifying isoelectric point of antibody via amino acid substitution in cdrCHUGAI PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 3679US9556264B2Humanized anti-epiregulin antibody, and cancer therapeutic agent comprising said antibody as active ingredientCHUGAI PHARMACEUTICAL CO LTD·Filed 2012·Granted Jan 31, 2017·5 cites·25 claims
- 3776US7709615B2Polynucleotides encoding anti-ganglioside antibodiesCHUGAI PHARMACEUTICAL CO LTD·Filed 2004·Granted May 4, 2010·11 cites·25 claims
- 3876US2022267822A1Methods for producing polypeptides by regulating polypeptide associationCHUGAI PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 3974US2020231688A1Antibody moleculesCHUGAI PHARMACEUTICAL CO LTD·Filed 2020·Application pending·0 cites
- 4073US2021206862A1Anti-il-6 receptor antibodyCHUGAI PHARMACEUTICAL CO LTD·Filed 2020·Application pending·0 cites
- 4168US2020002429A1Anti-nr10 antibody and use thereofCHUGAI PHARMACEUTICAL CO LTD·Filed 2019·Application pending·0 cites
- 4266US12473375B2Methods for controlling blood pharmacokinetics of antibodiesCHUGAI PHARMACEUTICAL CO LTD·Filed 2021·Granted Nov 18, 2025·0 cites·28 claims
- 4366US2011245473A1Anti-IL-6 Receptor AntibodyCHUGAI PHARMACEUTICAL CO LTD·Filed 2008·Application pending·0 cites
- 4466US2011129459A1Anti-nr10 antibody and use thereofCHUGAI PHARMACEUTICAL CO LTD·Filed 2008·Application pending·0 cites
- 4563US11576969B2AntiPlexin A1 agonist antibodyUNIV OSAKA·Filed 2020·Granted Feb 14, 2023·0 cites·13 claims
- 4663US2015175704A1Anti-nr10 antibody and use thereofCHUGAI PHARMACEUTICAL CO LTD·Filed 2014·Application pending·0 cites
- 4763US2019085085A1Anti-il-6 receptor antibodyCHUGAI PHARMACEUTICAL CO LTD·Filed 2018·Application pending·0 cites
- 4863US2012253016A1Antibody molecules that bind to il-6 receptorIGAWA TOMOYUKI·Filed 2012·Application pending·0 cites
- 4961US8298816B2Expression systems using mammalian beta-actin promoterTSUNODA HIROYUKI·Filed 2004·Granted Oct 30, 2012·1 cites·34 claims
- 5061US2013317203A1Anti-IL-6 Receptor AntibodyCHUGAI PHARMACEUTICAL CO LTD·Filed 2013·Application pending·0 cites
Showing the top 50 of 70 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Hiroyuki Tsunoda files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →